Valuation: AbbVie Inc.

Market Cap 500B 445B 412B 375B 704B 47,360B 715B 4,947B 1,945B 24,753B 1,874B 1,835B 79,129B P/E 2026 *
36.1x
P/E 2027 * 26.8x
Enterprise Value 562B 501B 464B 422B 791B 53,258B 804B 5,564B 2,188B 27,835B 2,108B 2,063B 88,983B EV / Sales 2026 *
8.31x
EV / Sales 2027 * 7.54x
Free-Float
95.71%
Yield 2026 *
2.43%
Yield 2027 * 2.55%
1 day+1.64%
1 week+4.88%
Current month+10.00%
1 month+8.79%
3 months+13.56%
6 months+41.25%
Current year+25.93%
1 week 275.97
Extreme 275.97
291.4
1 month 257.87
Extreme 257.87
291.4
Current year 190.75
Extreme 190.75
291.4
1 year 190.75
Extreme 190.75
291.4
3 years 135.85
Extreme 135.85
291.4
5 years 107.15
Extreme 107.15
291.4
10 years 55.06
Extreme 55.0623
291.4
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Free

Director

59 0.0000%
9/30/26 Free

Director

129 0.0000%
8/14/26 Exercice

Executive/Senior Manager

98,130 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
+1.89%+4.88%+23.99%+96.77% 500B
+4.57%+11.55%+60.85%+122.57% 1,106B
+2.37%+4.22%+33.75%+69.35% 612B
+2.35%+8.17%+38.46%+62.85% 367B
+2.97%+4.28%+71.52%+44.20% 354B
+1.63%+5.45%+20.80%+48.35% 286B
+1.60%+5.36%-0.24%+20.17% 256B
+2.43%+5.32%+43.34%+55.94% 230B
+1.73%+4.93%+26.07%+99.50% 190B
+1.83%+1.36%-27.70%-61.61% 170B
Average +2.19%+5.55%+29.08%+55.81% 407.05B
Weighted average by Cap. +2.75%+6.79%+38.19%+74.99%

Financials

2026 *2027 *
Net sales 67.63B 60.28B 55.84B 50.77B 95.27B 6,412B 96.84B 670B 263B 3,351B 254B 248B 10,712B 73.5B 65.52B 60.69B 55.18B 104B 6,969B 105B 728B 286B 3,642B 276B 270B 11,643B
Net income 13.94B 12.43B 11.51B 10.47B 19.64B 1,322B 19.97B 138B 54.3B 691B 52.31B 51.22B 2,209B 18.94B 16.89B 15.64B 14.22B 26.69B 1,796B 27.13B 188B 73.78B 939B 71.08B 69.59B 3,001B
Net Debt 62.21B 55.45B 51.37B 46.7B 87.64B 5,898B 89.08B 616B 242B 3,083B 233B 229B 9,854B 54.71B 48.77B 45.18B 41.08B 77.08B 5,187B 78.35B 542B 213B 2,711B 205B 201B 8,667B
Projected Income Statement - Annual - AbbVie Inc.
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-10-20 US$288.96 +2.22% 927,014
26-10-19 US$282.68 -0.96% 4,171,958
26-10-16 US$285.42 +0.71% 5,776,793
26-10-15 US$283.40 -0.03% 7,621,730
26-10-14 US$283.48 +3.32% 5,633,169
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - AbbVie Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
282.68USD
Average target price
282.61USD
Spread / Average Target
-0.03%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AbbVie Inc.
  1. Stock Market
  2. Stocks
  3. ABBV Stock